| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6277b021342bd0b6a9519eeb481d847 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2018-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a18e9ae18c5a0cd4a7499214d0d82d8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2c7e765f1e871620467c6c8de9f5001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81952d52b6ca4bf9b02ffdfed24e8ff1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45048a33a961455f7fdeebd3d0a54343 |
| publicationDate |
2019-06-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3498270-A1 |
| titleOfInvention |
Slow release formulations of cell cycle regulators and anti-cancer agents for local treatment of solid cancer |
| abstract |
The invention relates to the use of a cell cycle modulator capable of arresting the cell cycle in the S and/or G1 phase for the treatment of cancer of a body cavity. The cell cycle modulator comprises in a first composition comprising a first sustained release composition component, such as a thermoreversible hydrogel, and wherein said first composition is administered locally to the body cavity. Administration of the first composition is followed by administration of a second composition comprising at least one anti-cancer agent to the body cavity. |
| priorityDate |
2017-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |